Welcome Back |Sign in | Register
Your Position: Home > Inhibitors/Agonists > Cilomilast

View History

Cilomilast
prev zoom next

Name:Cilomilast

  • Catalog No.:
  • BCM007289
  • Chem Name:
  • 4-cyano-4-(3-cyclopentyloxy-4-methoxyphenyl)cyclohexane-1-carboxylic acid
  • Synonym:
  • Cilomilast; SB-207499
  • CAS No.:
  • 153259-65-5
  • EINECS:
  • 200-258-5
  • MDL No.:
  • MFCD00924373
  • Formula:
  • C20H25NO4
  • Molecular:
  • 343.42
  • Form:
  • White to beige powder
  • Storage:
  • Stored at -20°C
  • Wish  | Compare  | Referral bonuses
SKU Specification Brand Prices Stock Quantity Cart
BCM007289-10MG 10mg, Purity:98% BCM $260 1 Add Cart
BCM007289-50MG 50mg, Purity:98% BCM $785 1 Add Cart
For more quantities, please contact telephone:0755-85269922,Or send an email to:sales@biochemmall.com

Product Description

Attribute

Goods Tag

Related Products

 

Cilomilast (SB-207499) is a potent PDE4 inhibitor with an IC50 of 110 nM, anti-inflammatory activity and weak central nervous system activity. Phase 3.

 

Brand: BCM

 

Target: PDE

 

Signaling Pathways: Metabolism

 

In Vitro: Cilomilast produces a concentration-dependent increase in cAMP content in U937 cells. Cilomilast produces a concentration-dependent increase in cAMP content in U937 cells. In isolated human monocytes, Cilomilast and (R)-rolipram are equipotent at suppressing LPS-induced TNF-α formation with -log (IC50) of 7.0 and 7.2, respectively. Both Cilomilast and (R)-rolipram produces a modest prevention of fMLP-induced degranulation of human neutrophils. Cilomilast and (R)-rolipram are equipotent at suppressing neutrophil activation with -log (IC50) of 7.1 and 6.4, respectively. Cilomilast significantly decreases the expression of TNF-α in the cornea and IL-1α, IL-1β, and TNF-α in the conjunctivaas compared to vehicle control. Cilomilast treatment markedly decreases the presence of CD11b+ antigen-presenting cells in the central and peripheral cornea, and leads to decreased conjunctival expression of cytokines IL-6, IL-23, and IL-17. Moreover, Cilomilast decreases the expression of IL-17 and IL-23 in the draining lymph nodes. Cilomilast reduces TLR4 expression, IL-8 release and neutrophil chemotactic activity as well as it increased IP-10 release and lymphocyte chemotactic activity.

 

Melting Point: 157°C

 

Boiling Point: 549.1±50.0 °C(Predicted)

 

pKa: 4.45±0.25(Predicted)

 

Solubility: Soluble in DMSO; Soluble in Ethanol. Insoluble in Water.

 

Isomeric SMILES: COC1=C(C=C(C=C1)C2(CCC(CC2)C(=O)O)C#N)OC3CCCC3  

 

InChIKey: CFBUZOUXXHZCFB-UHFFFAOYSA-N  

 

InChI: InChI=1S/C20H25NO4/c1-24-17-7-6-15(12-18(17)25-16-4-2-3-5-16)20(13-21)10-8-14(9-11-20)19(22)23/h6-7,12,14,16H,2-5,8-11H2,1H3,(H,22,23)

 

Attribute
[Chem Name] 4-cyano-4-(3-cyclopentyloxy-4-methoxyphenyl)cyclohexane-1-carboxylic acid
[Synonym] Cilomilast; SB-207499
[CAS No.] 153259-65-5
[EINECS] 200-258-5
[MDL No.] MFCD00924373
[Formula] C20H25NO4
[Molecular] 343.42
[Form] White to beige powder
[Storage] Stored at -20°C

Goods Tag

User Comment(Total0User Comment Num)

  • No comment
Total 0 records, divided into1 pages. First Prev Next Last
Username: Anonymous user
E-mail:
Rank:
Content:
Verification code: captcha